Proceeds to advance pipeline of programmed cellular immunotherapies
By Devika Patel
Knoxville, Tenn., Aug. 8 – Fate Therapeutics, Inc. said it will conduct a $10.29 million private placement of stock.
The company will sell 5.25 million common shares at $1.96 per share. The price per share represents a 7.11% discount to the Aug. 5 closing share price of $2.11.
Settlement is expected Aug. 10.
Proceeds will be used to advance the company’s pipeline of programmed cellular immunotherapies and for general corporate purposes.
Based in San Diego, Fate is a clinical-stage biopharmaceutical company engaged in the development of programmed cellular therapeutics for the treatment of severe, life-threatening diseases.
| Issuer: | Fate Therapeutics, Inc.
|
| Issue: | Common shares
|
| Amount: | $10.29 million
|
| Shares: | 5.25 million
|
| Price: | $1.96
|
| Warrants: | No
|
| Pricing date: | Aug. 8
|
| Settlement date: | Aug. 10
|
| Stock symbol: | Nasdaq: FATE
|
| Stock price: | $2.11 at close Aug. 5
|
| Market capitalization: | $70.62 million
|
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.
